Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6821959 | 0.89 | ADORA1 (0.42) | ADORA1CASRIGF1RPTGDR2MAPK1 | |
| SCHEMBL6822330 | 0.85 | ADORA1 (0.41) | ADORA1CASRIGF1RPTGDR2TP53 | |
| SCHEMBL6822006 | 0.82 | ADORA1 (0.46) | ADORA1CASRIGF1RPTGDR2TP53 | |
| SCHEMBL6821431 | 0.81 | ADORA1 (0.51) | ADORA1IGF1RPTGDR2MAPK1PDE4B | |
| SCHEMBL6822483 | 0.81 | CMKLR1 (0.42) | ADORA1CASRSMN1; SMN2 | |
| SCHEMBL6822546 | 0.81 | ADORA1 (0.41) | ADORA1CASRIGF1RMAPT | |
| SCHEMBL6822058 | 0.81 | ADORA1 (0.42) | ADORA1CASRIGF1RTP53PTGER1 | |
| SCHEMBL6822257 | 0.81 | ADORA1 (0.43) | ADORA1CASRIGF1RTP53SMN1; SMN2 | |
| SCHEMBL6822033 | 0.81 | ADORA1 (0.41) | ADORA1IGF1RTP53MAPK1 | |
| SCHEMBL6824716 | 0.80 | ADORA1 (0.40) | ADORA1IGF1RMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | ADRB1, ADRA1D, ADRB3 | ADORA1 22/4885CASR 3643/4885IGF1R 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.